Sorrento Therpt Cmn (SRNE) 6.29 $SRNE
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
PR Newswire Europe - Mon Jul 11, 8:01AM CDT
An Immuno-Oncology Therapy with Many Potential Applications
SRNE: 6.29 (+0.10)
Sorrento Closes $150 Million Private Placement Investments
PR Newswire - Wed Jun 08, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"
, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs announced today that it has closed on $150 million related to the private placements of common stock and warrants previously announced by the company on April 4, 2016.
SRNE: 6.29 (+0.10)
Sorrento and 3SBio Announce CAR-T Joint Venture in China
PR Newswire - Tue Jun 07, 8:04AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" , an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today its subsidiary TNK Therapeutics, Inc. ("TNK" has entered into a joint venture agreement ("JVA" with Shenyang Sunshine Pharmaceutical Company Ltd ("3SBio" to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK's chimeric antigen receptor T cell ("CAR-T" technology targeting carcinoembryonic antigen ("CEA" positive cancers. 3SBio is a leading China-based biotechnology company focused on discovering, developing, manufacturing, and commercializing biopharmaceutical products.
SRNE: 6.29 (+0.10)
Sorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento" , an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that Dr. Henry Ji, President and CEO, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New York, NY. The Sorrento presentation is scheduled to begin at 9:00am EDT.
SRNE: 6.29 (+0.10)
Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody
PR Newswire - Mon May 16, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento" , an antibody-centric, clinical-stage biopharmaceutical company developing new therapies for cancer and other unmet medical needs announced that its partner, Mabtech Ltd., has successfully completed a combined Phase 2 & 3 clinical study in China for STI-004, a biosimilar antibody for Omalizumab (Xolair®). STI-004 met its primary endpoint in a multicenter, randomized, double-blind, placebo-controlled clinical trial.
SRNE: 6.29 (+0.10)
Wildcat Capital Issues Letter to Board of Sorrento Therapeutics
PR Newswire - Fri May 06, 8:00AM CDT
Wildcat Capital Management LLC ("Wildcat" , whose clients hold an ownership stake of 6.5% of the common stock of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (the "Company" or "Sorrento" , today sent a letter to the Company's Board of Directors (the "Board" urging the Board to take specific actions to remedy the ongoing destruction of significant shareholder value. In particular, the letter calls for the Board to immediately terminate and replace Dr. Henry Ji as Chief Executive Officer and to stop recently announced financing transactions to avoid further dilution to the existing shareholders. The letter also calls for the appointment of three Wildcat nominees to the Board to lead a special committee authorized to initiate a sales process for the Company.
SRNE: 6.29 (+0.10)
Sorrento closes private placement with Yuhan Corporation
PR Newswire - Mon May 02, 10:24AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento" , an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has closed its previously announced private placement of common stock and warrants with Yuhan Corporation (000100.KS; "Yuhan" of South Korea for gross proceeds of $10 million.
SRNE: 6.29 (+0.10)
Sorrento to Present at 2 Upcoming Conferences in New York City
PR Newswire - Mon May 02, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at 2 upcoming conferences in New York City:
SRNE: 6.29 (+0.10)
Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PR Newswire - Thu Apr 14, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today 3 poster presentations at the upcoming AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16 - 20, 2016.
SRNE: 6.29 (+0.10)
Sorrento to Present at the Jefferies Immuno-Oncology Summit
PR Newswire - Wed Apr 06, 11:53AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at the Jefferies Immuno-Oncology Summit on Thursday, April 7, 2016 from 7:55 am to 8:20 am EDT. The conference will take place at the Boston Harbor Hotel in Boston, MA.
SRNE: 6.29 (+0.10)
Sorrento Appoints Kevin M. Herde As Chief Financial Officer
PR Newswire - Tue Apr 05, 5:42PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, today announced that Kevin M. Herde has been appointed to the position of Executive Vice President & Chief Financial Officer.
SRNE: 6.29 (+0.10)
Sorrento Announces Definitive Agreements for up to $150 Million Private Placement
PR Newswire - Mon Apr 04, 7:22PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs company, today announced that it has entered into definitive agreements with institutional investors and its strategic corporate partner, Yuhan Corporation (000100.KS; Yuhan) of South Korea, whereby such investors will invest up to approximately $150 million in separate private placements in newly issued common stock (the "Shares" at $5.55 per share and receive warrants to purchase common stock with an exercise price of $8.50 per share (the "Warrants" .
SRNE: 6.29 (+0.10)
Sorrento to Present at the 28th Annual ROTH Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Henry Ji, Ph.D., Chairman and CEO, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 from 7:00 am to 7:30 am PDT in Salon 6 - Yellow. The conference will take place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.
SRNE: 6.29 (+0.10)
Global Cancer Pain Therapeutics Market 2015-2019 - Key Vendors are BioDelivery Sciences, ProStrakan Group, Teva Pharmaceuticals & Yamaha
M2 - Fri Jan 29, 6:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/vhmpcl/global_cancer) has announced the addition of the "Global Cancer Pain Therapeutics Market 2015-2019" report to their offering. The report forecasts the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020. To overcome the severe competition being posed, the key players and other vendors have started differentiating their drugs in an attempt to increase profits and avoid price competition. According to the report, the major driving factor for the global cancer pain therapeutics market is the high unmet need for appropriate drugs in the market. Further, the report states that the use of off-label drugs is another important challenge for the market. Key questions answered in this report: - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Companies Mentioned: - BioDelivery Sciences - ProStrakan Group - Teva Pharmaceuticals - Daiichi Sankyo - Eli-lilly - Galena Biopharma - Grunenthal Group - GW Pharmaceuticals - Hospira - Johnson & Johnson - Meda Pharmaceuticals - Orexo - Sanofi - Sorrento Therapeutics - WEX Pharmaceuticals. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Disease overview PART 06: Pipeline portfolio PART 07: Market landscape PART 08: Market segmentation by drug class PART 09: Geographical segmentation PART 10: Market drivers PART 11: Impact of drivers PART 12: Market challenges PART 13: Impact of drivers and challenges PART 14: Market trends PART 15: Vendor landscape PART 16: Vendor landscape PART 17: Key vendor analysis PART 18: Appendix For more information visit http://www.researchandmarkets.com/research/vh...bal_cancer
JNJ: 125.23 (+0.77), GALE: 0.44 (-0.03), SRNE: 6.29 (+0.10), PTIE: 2.70 (-0.01)
OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 48.06 (+0.69), IMGN: 2.78 (-0.01), PPHM: 0.37 (-0.01), SRNE: 6.29 (+0.10), CELG: 112.19 (+0.93)
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and Sorrento Therapeutics
ACCESSWIRE - Tue Jan 12, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 12, 2016 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Sorrento Therapeutics Inc. (NASDAQ: SRNE). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Monday, January 11, 2016, the NASDAQ Composite ended at 4,637.99, down 0.12%, the Dow Jones Industrial Average advanced 0.32%, to finish the day at 16,398.57, and the S&P 500 closed at 1,923.67, up 0.09%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PGNX: 5.85 (+0.04), SPPI: 6.87 (+0.05), RGLS: 3.57 (unch), SRNE: 6.29 (+0.10)
Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002
PR Newswire - Mon Jan 11, 6:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that its partner, MabTech Ltd. has successfully completed Phase 3 clinical trials in China for STI-001, a biosimilar/biobetter antibody for Cetuximab (Erbitux®) and STI-002, a biosimilar/biobetter antibody for Infliximab (Remicade®). Both STI-001 and STI-002 met their primary endpoints in confirmatory, randomized, controlled, two-part Phase 3 studies.
SRNE: 6.29 (+0.10)
Sorrento and Karolinska Institutet Establish Exclusive Partnership for Research and Development of Natural Killer Cell-based Therapies
PR Newswire - Mon Jan 11, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has formed an exclusive partnership with the world-renowned Karolinska Institutet (KI) in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies.
SRNE: 6.29 (+0.10)
Immunotherapy Inside the Cell Interview by The Life Sciences Report
Marketwired - Fri Jan 08, 8:00AM CST
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologies -- and the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc. -- with Lin, Followwill and Ram Selvaraju of Rodman and Renshaw.
ONCS: 1.82 (+0.03), SRNE: 6.29 (+0.10)
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
PR Newswire Europe - Mon Jul 11, 8:01AM CDT
An Immuno-Oncology Therapy with Many Potential Applications
SRNE: 6.29 (+0.10)
Sorrento Closes $150 Million Private Placement Investments
PR Newswire - Wed Jun 08, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"
, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs announced today that it has closed on $150 million related to the private placements of common stock and warrants previously announced by the company on April 4, 2016. SRNE: 6.29 (+0.10)
Sorrento and 3SBio Announce CAR-T Joint Venture in China
PR Newswire - Tue Jun 07, 8:04AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"
, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today its subsidiary TNK Therapeutics, Inc. ("TNK" has entered into a joint venture agreement ("JVA" with Shenyang Sunshine Pharmaceutical Company Ltd ("3SBio" to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK's chimeric antigen receptor T cell ("CAR-T" technology targeting carcinoembryonic antigen ("CEA" positive cancers. 3SBio is a leading China-based biotechnology company focused on discovering, developing, manufacturing, and commercializing biopharmaceutical products. SRNE: 6.29 (+0.10)
Sorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"
, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that Dr. Henry Ji, President and CEO, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New York, NY. The Sorrento presentation is scheduled to begin at 9:00am EDT. SRNE: 6.29 (+0.10)
Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody
PR Newswire - Mon May 16, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"
, an antibody-centric, clinical-stage biopharmaceutical company developing new therapies for cancer and other unmet medical needs announced that its partner, Mabtech Ltd., has successfully completed a combined Phase 2 & 3 clinical study in China for STI-004, a biosimilar antibody for Omalizumab (Xolair®). STI-004 met its primary endpoint in a multicenter, randomized, double-blind, placebo-controlled clinical trial. SRNE: 6.29 (+0.10)
Wildcat Capital Issues Letter to Board of Sorrento Therapeutics
PR Newswire - Fri May 06, 8:00AM CDT
Wildcat Capital Management LLC ("Wildcat"
, whose clients hold an ownership stake of 6.5% of the common stock of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (the "Company" or "Sorrento" , today sent a letter to the Company's Board of Directors (the "Board" urging the Board to take specific actions to remedy the ongoing destruction of significant shareholder value. In particular, the letter calls for the Board to immediately terminate and replace Dr. Henry Ji as Chief Executive Officer and to stop recently announced financing transactions to avoid further dilution to the existing shareholders. The letter also calls for the appointment of three Wildcat nominees to the Board to lead a special committee authorized to initiate a sales process for the Company. SRNE: 6.29 (+0.10)
Sorrento closes private placement with Yuhan Corporation
PR Newswire - Mon May 02, 10:24AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"
, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has closed its previously announced private placement of common stock and warrants with Yuhan Corporation (000100.KS; "Yuhan" of South Korea for gross proceeds of $10 million. SRNE: 6.29 (+0.10)
Sorrento to Present at 2 Upcoming Conferences in New York City
PR Newswire - Mon May 02, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at 2 upcoming conferences in New York City:
SRNE: 6.29 (+0.10)
Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PR Newswire - Thu Apr 14, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today 3 poster presentations at the upcoming AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16 - 20, 2016.
SRNE: 6.29 (+0.10)
Sorrento to Present at the Jefferies Immuno-Oncology Summit
PR Newswire - Wed Apr 06, 11:53AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at the Jefferies Immuno-Oncology Summit on Thursday, April 7, 2016 from 7:55 am to 8:20 am EDT. The conference will take place at the Boston Harbor Hotel in Boston, MA.
SRNE: 6.29 (+0.10)
Sorrento Appoints Kevin M. Herde As Chief Financial Officer
PR Newswire - Tue Apr 05, 5:42PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases, today announced that Kevin M. Herde has been appointed to the position of Executive Vice President & Chief Financial Officer.
SRNE: 6.29 (+0.10)
Sorrento Announces Definitive Agreements for up to $150 Million Private Placement
PR Newswire - Mon Apr 04, 7:22PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs company, today announced that it has entered into definitive agreements with institutional investors and its strategic corporate partner, Yuhan Corporation (000100.KS; Yuhan) of South Korea, whereby such investors will invest up to approximately $150 million in separate private placements in newly issued common stock (the "Shares"
at $5.55 per share and receive warrants to purchase common stock with an exercise price of $8.50 per share (the "Warrants" . SRNE: 6.29 (+0.10)
Sorrento to Present at the 28th Annual ROTH Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Henry Ji, Ph.D., Chairman and CEO, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 from 7:00 am to 7:30 am PDT in Salon 6 - Yellow. The conference will take place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.
SRNE: 6.29 (+0.10)
Global Cancer Pain Therapeutics Market 2015-2019 - Key Vendors are BioDelivery Sciences, ProStrakan Group, Teva Pharmaceuticals & Yamaha
M2 - Fri Jan 29, 6:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/vhmpcl/global_cancer) has announced the addition of the "Global Cancer Pain Therapeutics Market 2015-2019" report to their offering. The report forecasts the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020. To overcome the severe competition being posed, the key players and other vendors have started differentiating their drugs in an attempt to increase profits and avoid price competition. According to the report, the major driving factor for the global cancer pain therapeutics market is the high unmet need for appropriate drugs in the market. Further, the report states that the use of off-label drugs is another important challenge for the market. Key questions answered in this report: - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Companies Mentioned: - BioDelivery Sciences - ProStrakan Group - Teva Pharmaceuticals - Daiichi Sankyo - Eli-lilly - Galena Biopharma - Grunenthal Group - GW Pharmaceuticals - Hospira - Johnson & Johnson - Meda Pharmaceuticals - Orexo - Sanofi - Sorrento Therapeutics - WEX Pharmaceuticals. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Disease overview PART 06: Pipeline portfolio PART 07: Market landscape PART 08: Market segmentation by drug class PART 09: Geographical segmentation PART 10: Market drivers PART 11: Impact of drivers PART 12: Market challenges PART 13: Impact of drivers and challenges PART 14: Market trends PART 15: Vendor landscape PART 16: Vendor landscape PART 17: Key vendor analysis PART 18: Appendix For more information visit http://www.researchandmarkets.com/research/vh...bal_cancer
JNJ: 125.23 (+0.77), GALE: 0.44 (-0.03), SRNE: 6.29 (+0.10), PTIE: 2.70 (-0.01)
OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 48.06 (+0.69), IMGN: 2.78 (-0.01), PPHM: 0.37 (-0.01), SRNE: 6.29 (+0.10), CELG: 112.19 (+0.93)
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and Sorrento Therapeutics
ACCESSWIRE - Tue Jan 12, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 12, 2016 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Sorrento Therapeutics Inc. (NASDAQ: SRNE). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Monday, January 11, 2016, the NASDAQ Composite ended at 4,637.99, down 0.12%, the Dow Jones Industrial Average advanced 0.32%, to finish the day at 16,398.57, and the S&P 500 closed at 1,923.67, up 0.09%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PGNX: 5.85 (+0.04), SPPI: 6.87 (+0.05), RGLS: 3.57 (unch), SRNE: 6.29 (+0.10)
Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002
PR Newswire - Mon Jan 11, 6:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that its partner, MabTech Ltd. has successfully completed Phase 3 clinical trials in China for STI-001, a biosimilar/biobetter antibody for Cetuximab (Erbitux®) and STI-002, a biosimilar/biobetter antibody for Infliximab (Remicade®). Both STI-001 and STI-002 met their primary endpoints in confirmatory, randomized, controlled, two-part Phase 3 studies.
SRNE: 6.29 (+0.10)
Sorrento and Karolinska Institutet Establish Exclusive Partnership for Research and Development of Natural Killer Cell-based Therapies
PR Newswire - Mon Jan 11, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has formed an exclusive partnership with the world-renowned Karolinska Institutet (KI) in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies.
SRNE: 6.29 (+0.10)
Immunotherapy Inside the Cell Interview by The Life Sciences Report
Marketwired - Fri Jan 08, 8:00AM CST
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologies -- and the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc. -- with Lin, Followwill and Ram Selvaraju of Rodman and Renshaw.
ONCS: 1.82 (+0.03), SRNE: 6.29 (+0.10)
